SCHEMBL16640329

SCHEMBL16640329

CC(C)c1ccc(-n2c3ccccc3c3ncccc32)cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.35
SLC6A2 P23975 1/20 0.35
L3MBTL1 Q9Y468 4/20 0.34
KDM4E B2RXH2 4/20 0.34
ATM Q13315 2/20 0.34
REN P00797 1/20 0.34
NPC1 O15118 2/20 0.33
USP14 P54578 2/20 0.33
HSP90AA1 P07900 1/20 0.33
IDO1 P14902 1/20 0.33
MAPT P10636 3/20 0.33
LMNA P02545 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
RAB9A P51151 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21453894 0.90 USP14 (0.36) HTTSLC6A2L3MBTL1KDM4EREN
SCHEMBL16640324 0.87 ATM (0.46) HTTL3MBTL1KDM4EATMUSP14
SCHEMBL16640330 0.84 PDE4A (0.37) HTTL3MBTL1KDM4EATMMAPT
SCHEMBL16644618 0.83 L3MBTL1 (0.41) HTTSLC6A2L3MBTL1KDM4EATM
SCHEMBL16640348 0.82 L3MBTL1 (0.41) HTTL3MBTL1KDM4EATMREN
SCHEMBL13866678 0.81 KDM4E (0.39) HTTSLC6A2L3MBTL1KDM4EATM
SCHEMBL16640321 0.81 CDK4 (0.38) L3MBTL1KDM4EATMIDO1CYP1A2
SCHEMBL16640323 0.81 MAOA (0.43) SLC6A2L3MBTL1KDM4EATMCYP1A2
SCHEMBL23439034 0.80 CYP1A2 (0.46) HTTL3MBTL1KDM4EATMNPC1
SCHEMBL21008707 0.79 KDM4E (0.37) HTTL3MBTL1KDM4EATMNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11189808-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-11-30 US disclosed
US-20200152891-A1 PLATINUM COMPLEXES AND DEVICES UNIV ARIZONA STATE (US) 2020-05-14 US disclosed
US-10566553-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2020-02-18 US disclosed
US-9947881-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-17 US disclosed
US-9947881-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-17 US disclosed
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2017-01-12 US disclosed
US-9385329-B2 Platinum complexes and devices Arizona Board of Regents on behalf of Arizona State University and Universal Display Corporation (US) 2016-07-05 US disclosed
US-20150105556-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11189808-B2 Platinum complexes and devices OXA1L, OCIAD1, OCIAD2 HTT 2065/4885SLC6A2 3412/4885L3MBTL1 1502/4885
US-10566553-B2 Platinum complexes and devices OXA1L, OCIAD1, OCIAD2 HTT 2065/4885SLC6A2 3412/4885L3MBTL1 1502/4885
US-20200152891-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 HTT 2065/4885SLC6A2 3412/4885L3MBTL1 1502/4885
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 HTT 2065/4885SLC6A2 3412/4885L3MBTL1 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.